Vir Biotechnology (VIR) EBITDA Margin (2018 - 2026)
Vir Biotechnology (VIR) posted EBITDA Margin of 456172.41% for Q1 2026, down 609798.93% sequentially from 74.79% in Q4 2025, and down 45156994.0% YoY from N/an in Q1 2025.
Vir Biotechnology (VIR) EBITDA Margin (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported EBITDA Margin for 9 years, with the latest figure at 456172.41% in Q1 2026.
- Quarterly EBITDA Margin fell 45156994.0% year-over-year to 456172.41% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 720.14% (up 237958.0% YoY) and the FY2025 annual result came in at 699.18%, up 9210.0% from the prior year.
- EBITDA Margin slipped to 456172.41% in Q1 2026 per VIR's latest filing, from 74.79% in the prior quarter.
- Over five years, EBITDA Margin peaked at 82.26% in Q1 2022 and troughed at 456172.41% in Q1 2026.
- A 5-year average of 33727.91% and a median of 946.74% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2026: EBITDA Margin jumped 811025 bps in 2022, then sank 45156994 bps in 2026.
- Over 5 years, EBITDA Margin stood at 304.6% in 2022, then slumped by 172 bps to 828.12% in 2023, then dropped by 14 bps to 946.74% in 2024, then soared by 92 bps to 74.79% in 2025, then sank by 609799 bps to 456172.41% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 456172.41%, 74.79%, and 72267.92% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 30.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.75% |
| Mar 31, 2026 | -456,172.41% |
| Dec 31, 2025 | -74.79% |
| Sep 30, 2025 | -72,267.92% |
| Jun 30, 2025 | -9,754.28% |
| Mar 31, 2025 | -4,602.47% |
| Dec 31, 2024 | -946.74% |
| Sep 30, 2024 | -9,718.66% |
| Jun 30, 2024 | -5,158.70% |
| Mar 31, 2024 | -154.90% |
| Dec 31, 2023 | -828.12% |
| Sep 30, 2023 | -7,075.86% |
| Jun 30, 2023 | -5,667.26% |
| Mar 31, 2023 | -227.73% |
| Dec 31, 2022 | -304.60% |
| Sep 30, 2022 | 52.05% |
| Jun 30, 2022 | -554.34% |
| Mar 31, 2022 | 82.26% |
| Dec 31, 2021 | 70.35% |
| Sep 30, 2021 | -51.52% |